Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India. The oral drug is designed to provide an alternative to injectable weight ...

Eli Lilly yesterday announced the decision to stop ... This decision to cease ongoing Phase III development of the schizophrenia treatment is expected to result in a third-quarter charge to ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

We recently compiled a list of the 10 Best Reddit Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against the other stocks to buy ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Eli Lilly is to discontinue development of tabalumab for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) owing to disappointing results in two phase III trials.

US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Eli Lilly has released histological data from the Phase III VIVID-1 trial showing that its Crohn’s disease therapy Omvoh (mirikizumab) was superior to Johnson & Johnson’s (J&J) Stelara ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...